Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial

Prevalence and Predictors of Venous Thromboembolism or Mortality in Hospitalized COVID-19 Patients

(2021) Stuart Lance Cohen et al.   THROMBOSIS AND HAEMOSTASIS

Association Between Asymptomatic Proximal Deep Vein Thrombosis and Mortality in Acutely Ill Medical Patients

(2021) Gary E. Raskob et al.   Journal of the American Heart Association

Medically Ill hospitalized Patients for COVID-19 THrombosis Extended ProphyLaxis with rivaroxaban ThErapy: Rationale and Design of the MICHELLE Trial

(2021) Eduardo Ramacciotti et al.   AMERICAN HEART JOURNAL

Postdischarge thromboembolic outcomes and mortality of hospitalized patients with COVID-19: the CORE-19 registry

(2021) Dimitrios Giannis et al.   BLOOD

Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial

(2021) Renato D Lopes et al.   LANCET

Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19

(2021)   NEW ENGLAND JOURNAL OF MEDICINE

High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study

(2020) Julie Helms et al.   INTENSIVE CARE MEDICINE

Scientific and Standardization Committee Communication: Clinical Guidance on the Diagnosis, Prevention and Treatment of Venous Thromboembolism in Hospitalized Patients with COVID‐19

(2020) Alex C. Spyropoulos et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Post-discharge venous thromboembolism following hospital admission with COVID-19

(2020) Lara N Roberts et al.   BLOOD

Post-discharge thrombosis and hemorrhage in patients with COVID-19

(2020) Rushad Patell et al.   BLOOD

Prevention, Diagnosis, and Treatment of VTE in Patients With Coronavirus Disease 2019

(2020) Lisa K. Moores et al.   CHEST

Post-Discharge Prophylaxis With Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill Patients

(2020) Alex C. Spyropoulos et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Anticoagulant interventions in hospitalized patients with COVID‐19: A scoping review of randomized controlled trials and call for international collaboration

(2020) Tobias Tritschler et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Guidance for the Management of Patients with Vascular Disease or Cardiovascular Risk Factors and COVID-19: Position Paper from VAS-European Independent Foundation in Angiology/Vascular Medicine

(2020) Grigoris T. Gerotziafas et al.   THROMBOSIS AND HAEMOSTASIS

Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness

(2018) Alex C. Spyropoulos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients

(2016) Alexander T. Cohen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH

(2015) S. Kaatz et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Extended-Duration Venous Thromboembolism Prophylaxis in Acutely Ill Medical Patients With Recently Reduced Mobility

(2013) Russell D. Hull   ANNALS OF INTERNAL MEDICINE

Rivaroxaban for Thromboprophylaxis in Acutely Ill Medical Patients

(2013) Alexander T. Cohen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Apixaban versus Enoxaparin for Thromboprophylaxis in Medically Ill Patients

(2011) Samuel Z. Goldhaber et al.   NEW ENGLAND JOURNAL OF MEDICINE